AVIR Stock Summary and Trading Ideas (Atea Pharmaceuticals | NASDAQ:AVIR)

Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.

Atea Pharmaceuticals trades on the NASDAQ stock market under the symbol AVIR.

As of November 5, 2026, AVIR stock price declined to $4.25 with 68,250 million shares trading.

AVIR has a beta of 1.23, meaning it tends to be more sensitive to market movements. AVIR has a correlation of 0.06 to the broad based SPY ETF.

AVIR has a market cap of $340.87 million. This is considered a Small Cap stock.

In the last 3 years, AVIR traded as high as $6.45 and as low as $2.46.

The top ETF exchange traded funds that AVIR belongs to (by Net Assets): VTI, IWM, VXF, IWN, DFAS.

AVIR has outperformed the market in the last year with a price return of +32.4% while the SPY ETF gained +10.8%. However, in the short term, AVIR had mixed performance relative to the market. It has underperformed in the last 3 months, returning -9.6% vs -3.8% return in SPY. But in the last 2 weeks, AVIR shares have fared better than the market returning +4.2% compared to SPY -4.2%.

AVIR support price is $4.26 and resistance is $4.66 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AVIR shares will trade within this expected range on the day.